Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.59 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.59 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14357447 | 0.86 | NPSR1 (0.62) | NPSR1RAB9AGAALMNAMAPT | |
| SCHEMBL15903699 | 0.83 | NPSR1 (0.50) | NPSR1RAB9AGAALMNAMAPT | |
| SCHEMBL15046562 | 0.80 | SMN1; SMN2 (0.62) | NPSR1GAALMNAMAPTMEN1 | |
| SCHEMBL15920579 | 0.79 | RAB9A (0.47) | NPSR1RAB9AGAALMNAMAPT | |
| SCHEMBL11585645 | 0.79 | KDM4E (0.49) | NPSR1RAB9AGAALMNAMAPT | |
| SCHEMBL13390916 | 0.79 | GAA (0.45) | NPSR1RAB9AGAALMNAMAPT | |
| SCHEMBL14387832 | 0.79 | GAA (0.45) | NPSR1RAB9AGAALMNAMAPT | |
| SCHEMBL7479419 | 0.77 | ALDH1A1 (0.73) | NPSR1GAALMNAMAPTMEN1 | |
| SCHEMBL30817652 | 0.77 | ALDH1A1 (0.73) | NPSR1GAALMNAMAPTMEN1 | |
| SCHEMBL30817653 | 0.77 | ALDH1A1 (0.73) | NPSR1GAALMNAMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0196522-B1 | 2-AMINO-4-TRICHLOROMETHYL PYRIDINE, PROCESS FOR ITS PREPARATION AND ITS USE AS A NITRIFICATION INHIBITOR | BASF Aktiengesellschaft (DE) | 1989-07-12 | — | — | EP | claimed |
| US-4699983-A | 2-amino-4-trichloromethylpyridine and its preparation | BASF AKTIENGESELLSCHAFT (DE) | 1987-10-13 | — | — | US | claimed |
| EP-0196522-A1 | 2-Amino-4-trichloromethyl pyridine, process for its preparation and its use as a nitrification inhibitor | BASF Aktiengesellschaft (DE) | 1986-10-08 | — | — | EP | claimed |
| US-8106064-B2 | administering 1-[2-Chloro-6-(4-methoxy-benzylamino)-pyridin-4-ylmethyl]-6-(3-[1,3]dioxolan-2-yl-5-methyl-phenoxy)-5-isopropyl-1H-pyrimidine-2,4-dione viricide to treat AIDS | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-01-31 | — | — | US | disclosed |
| US-8106064-B2 | administering 1-[2-Chloro-6-(4-methoxy-benzylamino)-pyridin-4-ylmethyl]-6-(3-[1,3]dioxolan-2-yl-5-methyl-phenoxy)-5-isopropyl-1H-pyrimidine-2,4-dione viricide to treat AIDS | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-01-31 | — | — | US | disclosed |
| EP-1494671-B1 | 1-(4-PIPERIDINYL)BENZIMIDAZOLONES AS HISTAMINE H3 ANTAGONISTS | SCHERING CORP (US) | 2011-10-19 | — | — | EP | disclosed |
| US-20100093692-A1 | PIPERIDINYL-PIPERIDINE AND PIPERAZINYL-PIPERIDINE FOR USE IN THE TREATMENT OF DIABETES OR PAIN | SCHERING CORPORATION SECHERING-PLOUGH CORPORATION (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093692-A1 | PIPERIDINYL-PIPERIDINE AND PIPERAZINYL-PIPERIDINE FOR USE IN THE TREATMENT OF DIABETES OR PAIN | SCHERING CORPORATION SECHERING-PLOUGH CORPORATION (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100034827-A1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| US-20100034827-A1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| EP-2044037-A2 | HIV REVERSE TRANSCRIPTASE INHIBITORS | Gilead Sciences, Inc. (US) | 2009-04-08 | — | — | EP | disclosed |
| CN-1147205-A | antithrombotic agent | LILLY CO ELI (US) | 1997-04-09 | — | — | CN | disclosed |
| EP-0672658-A1 | Antithrombotic agents | ELI LILLY AND COMPANY (US) | 1995-09-20 | — | — | EP | disclosed |
| WO-1995023609-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1995-09-08 | — | — | WO | disclosed |
| US-5360796-A | Treatment of hypoxia, anoxia or ischemia | G. D. SEARLE & CO. (US) | 1994-11-01 | — | — | US | disclosed |
| EP-0436831-A2 | Imidazo[1,2-a]pyridinylalkyl compounds for treatment of neurotoxic injury | G.D. Searle & Co. (US) | 1991-07-17 | — | — | EP | disclosed |
| WO-1991008211-A1 | IMIDAZO[1,2-a]PYRIDINYLALKYL COMPOUNDS FOR TREATMENT OF NEUROTOXIC INJURY | G.D. SEARLE & CO. (US) | 1991-06-13 | — | — | WO | disclosed |
| EP-0196522-B1 | 2-AMINO-4-TRICHLOROMETHYL PYRIDINE, PROCESS FOR ITS PREPARATION AND ITS USE AS A NITRIFICATION INHIBITOR | BASF Aktiengesellschaft (DE) | 1989-07-12 | — | — | EP | disclosed |
| US-4699983-A | 2-amino-4-trichloromethylpyridine and its preparation | BASF AKTIENGESELLSCHAFT (DE) | 1987-10-13 | — | — | US | disclosed |
| EP-0196522-A1 | 2-Amino-4-trichloromethyl pyridine, process for its preparation and its use as a nitrification inhibitor | BASF Aktiengesellschaft (DE) | 1986-10-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100034827-A1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | POLR2E, POLRMT, POLR2H | NPSR1 4400/4885RAB9A 3082/4885GAA 356/4885 |
| US-20100093692-A1 | PIPERIDINYL-PIPERIDINE AND PIPERAZINYL-PIPERIDINE FOR USE IN THE TREATMENT OF DIABETES OR PAIN | GPR119, ATF4, GID4 | NPSR1 781/4885RAB9A 2235/4885GAA 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.